Nöromusküler Kavşak Hastalıkları
Özet
Nöromüsküler kavşak hastalıkları, motor nöronların presinaptik uçlarından salınan nörotransmitterlerin postsinaptik kas membranındaki reseptörlerle etkileşimini bozan ve bu nedenle kas kontraksiyonunda fonksiyonel yetersizliklere yol açan bir grup klinik durumu tanımlar. Bu hastalıklar, nöromüsküler iletişimdeki bozuklukların bir sonucu olarak farklı klinik tablolarla seyredebilir ve bu tablolar etkilenen yapıya bağlı olarak kas güçsüzlüğünden otonomik disfonksiyona, hatta solunum kaslarının tutulması durumunda yaşamı tehdit eden solunum yetmezliğine kadar değişkenlik gösterebilir. Patofizyolojik olarak, bu hastalıkların temelinde otoimmün süreçler (örneğin, Myastenia Gravis ve Lambert-Eaton Myastenik Sendromu), genetik mutasyonlar (Konjenital Myastenik Sendromlar) veya toksinlerin nöromüsküler bileşkeye yönelik direkt etkileri (Botulizm) gibi heterojen mekanizmalar bulunmaktadır. D Tanısal süreçte, kapsamlı ve multidisipliner bir değerlendirme esastır. Klinik bulguların detaylı bir şekilde incelenmesinin yanı sıra, serolojik testler, elektrofizyolojik incelemeler ve radyolojik görüntüleme yöntemlerinin entegre bir yaklaşımla kullanılması gerekmektedir. Tedavi yaklaşımları, hastalığın etiyolojisine ve klinik şiddetine göre geniş bir yelpazeyi kapsar. Semptomatik yönetimden immün modülatör tedavilere, biyolojik ajanlardan cerrahi müdahalelere kadar çeşitli stratejiler, hastanın bireysel özelliklerine göre özelleştirilir. Bu hastalıkların yönetiminde multidisipliner bir yaklaşım benimsenmesi, klinik sonuçların iyileştirilmesi ve hastaların yaşam kalitesinin artırılmasında temel bir öneme sahiptir.
Referanslar
Evoli A. Myasthenia gravis: new developments in research and treatment. Curr Opin Neurol. 2017;30(5):464-470. doi:10.1097/WCO.0000000000000473
Salari N, Fatahi B, Bartina Y, et al. Global prevalence of myasthenia gravis and the effectiveness of common drugs in its treatment: a systematic review and meta-analysis. J Transl Med. 2021;19(1):516. Published 2021 Dec 20. doi:10.1186/s12967-021-03185-7
Breiner A, Widdifield J, Katzberg HD, et al. Epidemiology of myasthenia gravis in Ontario, Canada. Neuromuscul Disord. 2016;26(1):41-46. doi:10.1016/j.nmd.2015.10.009
Huang X, Li Y, Feng H, et al. Clinical Characteristics of Juvenile Myasthenia Gravis in Southern China. Front Neurol. 2018;9:77. Published 2018 Feb 27. doi:10.3389/fneur.2018.00077
Boldingh MI, Maniaol AH, Brunborg C, et al. Geographical Distribution of Myasthenia Gravis in Northern Europe--Results from a Population-Based Study from Two Countries. Neuroepidemiology. 2015;44(4):221-231. doi:10.1159/000431036
Menon D, Bril V. Pharmacotherapy of Generalized Myasthenia Gravis with Special Emphasis on Newer Biologicals. Drugs. 2022;82(8):865-887. doi:10.1007/s40265-022-01726-y
Gilhus NE. Myasthenia Gravis. N Engl J Med. 2017;376(13):e25. doi:10.1056/NEJMc1701027
Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology. 2016;87(4):419-425. doi:10.1212/WNL.0000000000002790
Akaishi T, Suzuki Y, Imai T, et al. Response to treatment of myasthenia gravis according to clinical subtype. BMC Neurol. 2016;16(1):225. Published 2016 Nov 17. doi:10.1186/s12883-016-0756-3
Lazaridis K, Tzartos SJ. Autoantibody Specificities in Myasthenia Gravis; Implications for Improved Diagnostics and Therapeutics. Front Immunol. 2020;11:212. Published 2020 Feb 14. doi:10.3389/fimmu.2020.00212
Deymeer F. Myasthenia Gravis'te tedavi. Turkiye Klinikleri Journal of Internal Medical Sciences. 2005,1.22:38-43.
Markowiak T, Hofmann HS, Ried M. Classification and staging of thymoma. J Thorac Dis. 2020;12(12):7607-7612. doi:10.21037/jtd-2019-thym-01
Pasnoor M, Wolfe GI, Nations S, et al. Clinical findings in MuSK-antibody positive myasthenia gravis: a U.S. experience. Muscle Nerve. 2010;41(3):370-374. doi:10.1002/mus.21533
Guptill JT, Sanders DB, Evoli A. Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. Muscle Nerve. 2011;44(1):36-40. doi:10.1002/mus.22006
Grob D, Arsura EL, Brunner NG, et al. The course of myasthenia gravis and therapies affecting outcome. Ann N Y Acad Sci. 1987;505:472-499. doi:10.1111/j.1749-6632.1987.tb51317.x
Oh SJ, Kuruoglu R. Chronic limb-girdle myasthenia gravis. Neurology. 1992;42(6):1153-1156. doi:10.1212/wnl.42.6.1153
Wang L, Zhang Y, He M. Clinical predictors for the prognosis of myasthenia gravis. BMC Neurol. 2017;17(1):77. Published 2017 Apr 19. doi:10.1186/s12883-017-0857-7
Deymeer F. History of Myasthenia Gravis Revisited. Noro Psikiyatr Ars. 2020;58(2):154-162. Published 2020 Nov 7. doi:10.29399/npa.27315
Rodríguez Cruz PM, Al-Hajjar M, Huda S, et al. Clinical Features and Diagnostic Usefulness of Antibodies to Clustered Acetylcholine Receptors in the Diagnosis of Seronegative Myasthenia Gravis. JAMA Neurol. 2015;72(6):642-649. doi:10.1001/jamaneurol.2015.0203
Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 2015;14(10):1023-1036. doi:10.1016/S1474-4422(15)00145-3
Evoli A, Antonini G, Antozzi C, et al. Italian recommendations for the diagnosis and treatment of myasthenia gravis. Neurol Sci. 2019;40(6):1111-1124. doi:10.1007/s10072-019-03746-1
AAEM Quality Assurance Committee. American Association of Electrodiagnostic Medicine. Practice parameter for repetitive nerve stimulation and single fiber EMG evaluation of adults with suspected myasthenia gravis or Lambert-Eaton myasthenic syndrome: summary statement. Muscle Nerve. 2001;24(9):1236-1238. doi:10.1002/mus.1139
Fakiri MO, Tavy DL, Hama-Amin AD, et al. Accuracy of the ice test in the diagnosis of myasthenia gravis in patients with ptosis. Muscle Nerve. 2013;48(6):902-904. doi:10.1002/mus.23857
Oflazer P, Durmuş-Tekçe H, Deymeer F. Kas ve Nöromüsküler Kavşak Hastalıkları, İtf Nöroloji E-kitabı, 2020. Available at: http://www.itfnoroloji.org/kas/kasindex3.htm. Accessed Sep 7, 2024.
Sanders DB, Evoli A. Immunosuppressive therapies in myasthenia gravis. Autoimmunity. 2010;43(5-6):428-435. doi:10.3109/08916930903518107
Kerty E, Elsais A, Argov Z, et al. EFNS/ENS Guidelines for the treatment of ocular myasthenia. Eur J Neurol. 2014;21(5):687-693. doi:10.1111/ene.12359
Lotan I, Hellmann MA, Wilf-Yarkoni A, et al. Exacerbation of myasthenia gravis following corticosteroid treatment: what is the evidence? A systematic review. J Neurol. 2021;268(12):4573-4586. doi:10.1007/s00415-020-10264-0
Gungor-Tuncer O, Yilmaz V, Toker A, et al. Prompt Response to Prednisone Predicts Benign Course in MuSK-MG. Eur Neurol. 2017;78(3-4):137-142. doi:10.1159/000479228
Palace J, Newsom-Davis J, Lecky B. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology. 1998;50(6):1778-1783. doi:10.1212/wnl.50.6.1778
Muscle Study Group. A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology. 2008;71(6):394-399. doi:10.1212/01.wnl.0000312373.67493.7f
Sanders DB, Hart IK, Mantegazza R, et al. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology. 2008;71(6):400-406. doi:10.1212/01.wnl.0000312374.95186.cc
Heckmann JM, Rawoot A, Bateman K, et al. A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis. BMC Neurol. 2011;11:97. Published 2011 Aug 5. doi:10.1186/1471-2377-11-97
Tindall RS, Phillips JT, Rollins JA, et al. A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann N Y Acad Sci. 1993;681:539-551. doi:10.1111/j.1749-6632.1993.tb22937.x
Adiao KJB, Espiritu AI, Roque VLA, et al. Efficacy and tolerability of subcutaneously administered immunoglobulin in myasthenia gravis: A systematic review. J Clin Neurosci. 2020;72:316-321. doi:10.1016/j.jocn.2019.08.113
Alcantara M, Sarpong E, Barnett C, et al. Chronic immunoglobulin maintenance therapy in myasthenia gravis. Eur J Neurol. 2021;28(2):639-646. doi:10.1111/ene.14547
Guptill JT, Juel VC, Massey JM, et al. Effect of therapeutic plasma exchange on immunoglobulins in myasthenia gravis. Autoimmunity. 2016;49(7):472-479. doi:10.1080/08916934.2016.1214823
Evoli A, Di Schino C, Marsili F, et al. Successful treatment of myasthenia gravis with tacrolimus. Muscle Nerve. 2002;25(1):111-114. doi:10.1002/mus.10018
Minami N, Fujiki N, Doi S, et al. Five-year follow-up with low-dose tacrolimus in patients with myasthenia gravis. J Neurol Sci. 2011;300(1-2):59-62. doi:10.1016/j.jns.2010.09.033
Marino M, Basile U, Spagni G, et al. Long-Lasting Rituximab-Induced Reduction of Specific-But Not Total-IgG4 in MuSK-Positive Myasthenia Gravis. Front Immunol. 2020;11:613. Published 2020 May 5. doi:10.3389/fimmu.2020.00613
Di Stefano V, Lupica A, Rispoli MG, et al. Rituximab in AChR subtype of myasthenia gravis: systematic review. J Neurol Neurosurg Psychiatry. 2020;91(4):392-395. doi:10.1136/jnnp-2019-322606
Howard JF Jr, Utsugisawa K, Benatar M, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study [published correction appears in Lancet Neurol. 2017 Dec;16(12):954. doi: 10.1016/S1474-4422(17)30377-0]. Lancet Neurol. 2017;16(12):976-986. doi:10.1016/S1474-4422(17)30369-1
Mantegazza R, Wolfe GI, Muppidi S, et al. Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension. Neurology. 2021;96(4):e610-e618. doi:10.1212/WNL.0000000000011207
Buckingham JM, Howard FM Jr, Bernatz PE, et al. The value of thymectomy in myasthenia gravis: a computer-assisted matched study. Ann Surg. 1976;184(4):453-458. doi:10.1097/00000658-197610000-00008
Rodriguez M, Gomez MR, Howard FM Jr, et al. Myasthenia gravis in children: long-term follow-up. Ann Neurol. 1983;13(5):504-510. doi:10.1002/ana.410130506
Massey JM, De Jesus-Acosta C. Pregnancy and myasthenia gravis. Continuum (Minneap Minn). 2014;20(1 Neurology of Pregnancy):115-127. doi:10.1212/01.CON.0000443840.33310.bd
Eaton LM, Lambert EH. Electromyography and electric stimulation of nerves in diseases of motor unit; observations on myasthenic syndrome associated with malignant tumors. J Am Med Assoc. 1957;163(13):1117-1124. doi:10.1001/jama.1957.02970480021005
Schoser B, Eymard B, Datt J, et al. Lambert-Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer [published correction appears in J Neurol. 2017 Sep;264(9):1864. doi: 10.1007/s00415-017-8556-2]. J Neurol. 2017;264(9):1854-1863. doi:10.1007/s00415-017-8541-9
Wirtz PW, Smallegange TM, Wintzen AR, et al. Differences in clinical features between the Lambert-Eaton myasthenic syndrome with and without cancer: an analysis of 227 published cases. Clin Neurol Neurosurg. 2002;104(4):359-363. doi:10.1016/s0303-8467(02)00054-9
Verschuuren J, Strijbos E, Vincent A. Neuromuscular junction disorders. Handb Clin Neurol. 2016;133:447-466. doi:10.1016/B978-0-444-63432-0.00024-4
Kesner VG, Oh SJ, Dimachkie MM, et al. Lambert-Eaton Myasthenic Syndrome. Neurol Clin. 2018;36(2):379-394. doi:10.1016/j.ncl.2018.01.008
Crone C, Christiansen I, Vissing J. Myopathic EMG findings and type II muscle fiber atrophy in patients with Lambert-Eaton myasthenic syndrome. Clin Neurophysiol. 2013;124(9):1889-1892. doi:10.1016/j.clinph.2013.02.115
Hülsbrink R, Hashemolhosseini S. Lambert-Eaton myasthenic syndrome - diagnosis, pathogenesis and therapy. Clin Neurophysiol. 2014;125(12):2328-2336. doi:10.1016/j.clinph.2014.06.031
Engel AG, Shen XM, Selcen D, et al. Congenital myasthenic syndromes: pathogenesis, diagnosis, and treatment [published correction appears in Lancet Neurol. 2015 May;14(5):461. doi: 10.1016/S1474-4422(15)00010-1]. Lancet Neurol. 2015;14(4):420-434. doi:10.1016/S1474-4422(14)70201-7
Schara U, Della Marina A, Abicht A. Congenital myasthenic syndromes: current diagnostic and therapeutic approaches. Neuropediatrics. 2012;43(4):184-193. doi:10.1055/s-0032-1323850
Mülayim S, Uludağ B, Karasoy H. Konjenital miyastenik sendromlarda elektrofizyolojik özellikler. Ege Tıp Dergisi / Ege Journal of Medicine. 2008;47(1):15-19.
Jagtap SA, Abraham K, Sarada C, et al. Congenital myasthenic syndromes: Natural history and long-term prognosis. Ann Indian Acad Neurol. 2013;16(3):338-341. doi:10.4103/0972-2327.116918
Arslan Y, Tokuçoğlu F, Kaya A, et al. Geç tanı konjenital miyastenik sendrom. Dokuz Eylül Üniversitesi Tıp Fakültesi Dergisi. 2016,30.2:85-88.
Ekmekçi H, Özerol İH, Yılmaz H. Botulizm. Journal of Turgut Ozal Medical Center. 1998,5.1.
Todd EC. Costs of acute bacterial foodborne disease in Canada and the United States. Int J Food Microbiol. 1989;9(4):313-326. doi:10.1016/0168-1605(89)90099-8
Terranova W, Palumbo JN, Breman JG. Ocular findings in botulism type B. JAMA. 1979;241(5):475-477.
Friedman DI, Fortanasce VN, Sadun AA. Tonic pupils as a result of botulism. Am J Ophthalmol. 1990;109(2):236-237. doi:10.1016/s0002-9394(14)76000-3
Simcock PR, Kelleher S, Dunne JA. Neuro-ophthalmic findings in botulism type B. Eye (Lond). 1994;8 ( Pt 6):646-648. doi:10.1038/eye.1994.160
Woodruff BA, Griffin PM, McCroskey LM, et al. Clinical and laboratory comparison of botulism from toxin types A, B, and E in the United States, 1975-1988. J Infect Dis. 1992;166(6):1281-1286. doi:10.1093/infdis/166.6.1281
Hughes JM, Blumenthal JR, Merson MH, et al. Clinical features of types A and B food-borne botulism. Ann Intern Med. 1981;95(4):442-445. doi:10.7326/0003-4819-95-4-442
Jankovic J, Schwartz K, Donovan DT. Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm. J Neurol Neurosurg Psychiatry. 1990;53(8):633-639. doi:10.1136/jnnp.53.8.633
Rao AK, Sobel J, Chatham-Stephens K, et al. Clinical Guidelines for Diagnosis and Treatment of Botulism, 2021. MMWR Recomm Rep. 2021;70(2):1-30. Published 2021 May 7. doi:10.15585/mmwr.rr7002a1
Chalk CH, Benstead TJ, Pound JD, et al. Medical treatment for botulism. Cochrane Database Syst Rev. 2019;4(4):CD008123. Published 2019 Apr 17. doi:10.1002/14651858.CD008123.pub4
O'Horo JC, Harper EP, El Rafei A, et al. Efficacy of Antitoxin Therapy in Treating Patients With Foodborne Botulism: A Systematic Review and Meta-analysis of Cases, 1923-2016. Clin Infect Dis. 2017;66(suppl_1):S43-S56. doi:10.1093/cid/cix815
